22. New Drugs in the Treatment of Portal Hypertension

  1. Roberto de Franchis MD, AGAF Professor of Gastroenterology Head
  1. María Gabriela Delgado MD1,
  2. Susana Seijo MD1 and
  3. Jaime Bosch MD2

Published Online: 17 NOV 2010

DOI: 10.1002/9781444393989.ch22

Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition

Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition

How to Cite

Delgado, M. G., Seijo, S. and Bosch, J. (2011) New Drugs in the Treatment of Portal Hypertension, in Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition (ed R. de Franchis), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444393989.ch22

Editor Information

  1. Department of Medical Sciences, University of Milan, and Gastroenterology 3 Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Mangiagalli and Regina Elena Foundation, Milan, Italy

Author Information

  1. 1

    Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain

  2. 2

    Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain

Publication History

  1. Published Online: 17 NOV 2010
  2. Published Print: 14 JAN 2011

ISBN Information

Print ISBN: 9781444334494

Online ISBN: 9781444393989

SEARCH

Keywords:

  • new drugs, in portal hypertension treatment;
  • portal hypertension management - improving dramatically over the decades;
  • better understanding of mechanisms - portal hypertension, and effective and safe pharmacological agents;
  • failures of pharmacological therapy - insufficient reduction in portal pressure gradient (HVPG);
  • new targets in treatment of portal hypertension;
  • advances in knowledge of pathophysiological mechanisms - new targets for correcting portal hypertension;
  • patients, not having a “good” haemodynamic response to NSBBs - and combination therapy;
  • Carvedilol, portal pressure decrease - decreasing heart rate and cardiac index, and splanchnic vasoconstriction;
  • tetrahydrobiopterin (BH4), essential cofactor - for adequate generation of NO by endothelial nitric oxide synthase (eNOS);
  • inhibiting hyper-response to vasoconstrictors - at intrahepatic circulation COX-derived prostanoids

Summary

This chapter contains sections titled:

  • Rational basis for drug therapy

  • New beta-blockers

  • Treatments aimed at diminishing intrahepatic resistance

  • Angiogenesis in portal hypertension

  • Acknowledgments

  • References